The purpose of the study is to evaluate the safety and tolerability of two doses of psilocybin (25 mg each), given one month apart, in young adults aged 16 to 35 years who have Anorexia Nervosa. The treatment will be administered with psychological support and compared to the standard care, known as Treatment as Usual (TAU). Participants will receive the treatment orally in capsule form.

Throughout the study, researchers will monitor for any adverse events, which are any unwanted effects that may occur during the trial. The study will also look at changes in anxiety, life satisfaction, and other psychological factors, as well as improvements in weight and symptoms of Anorexia Nervosa. The goal is to see if the treatment can help achieve and maintain weight restoration and psychological well-being, while reducing symptoms of the disorder.

The study will use a combination of advanced imaging techniques, including PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging), to observe brain activity and structure. Participants will undergo these imaging tests to measure serotonin activity and brain connectivity. The trial will also involve eye-tracking to study gaze patterns during food choice tasks, as well as questionnaires to assess eating behaviors and anxiety levels.

The purpose of the study is to evaluate differences in serotonin transmission in the brain networks that control food intake between individuals with anorexia nervosa and those without the disorder. The trial will help researchers better understand the underlying brain mechanisms of anorexia nervosa, potentially leading to improved treatments in the future. Participants will receive an injection of sodium chloride solution as part of the study procedures.

The study compares ORE-001 to placebo to determine if the medication can help patients feel less full after meals and improve their ability to eat. The medication is taken by mouth and can be adjusted to different doses based on individual needs, up to 400 mg per day. The total treatment period lasts for 28 days.

During the study, researchers will monitor various aspects of patients’ health, including changes in feelings of fullness, digestive symptoms, body weight, food intake, sleep patterns, and overall well-being. The study will also measure certain substances in the body that are related to feelings of hunger and fullness. This is done to better understand how the medication works and ensure it is safe for patients.

The purpose of this study is to explore whether ERT can help improve both psychological and physical symptoms in girls with anorexia nervosa. The study is designed as an open-label trial, meaning that both the researchers and participants know what treatment is being administered. If the results are promising, this could lead to a larger study comparing ERT with a placebo. The trial will involve participants using the estradiol patch over a period of time, with regular assessments to monitor changes in symptoms and overall health.

Participants in the study will be monitored for changes in anxiety levels, specific symptoms of anorexia, and other health indicators such as hormone levels and cognitive performance. The study aims to determine if ERT is a feasible and effective treatment option for anorexia nervosa, potentially offering a new approach to managing this challenging condition. The findings could pave the way for incorporating ERT into clinical practice, providing additional treatment options for patients with anorexia nervosa.

Participants in the study will receive either donepezil or a , which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The treatment will be administered orally, and the study will last for a period of three months, during which participants will be monitored for changes in their symptoms and overall health.

The primary goal of the study is to observe any improvements in the symptoms of anorexia nervosa, such as changes in eating habits and body image perception. Additionally, the study will track other health indicators, including body mass index and psychological assessments, to gather comprehensive data on the effects of donepezil. Participants will undergo various tests and assessments at different points throughout the study to measure these changes. The study will also monitor for any potential side effects or adverse reactions to the medication. The findings from this trial could provide valuable insights into new treatment options for individuals with anorexia nervosa.